Leveraging nanochannels for universal, zero-order drug delivery in vivo

Journal of Controlled Release

Volumn 172, Issue 3, 2013, Pages 1011-1019

  Ferrati, Silvia ^a   Fine, Daniel ^a   You, Junping ^a,b   De Rosa, Enrica ^a   Hudson, Lee ^c   Zabre, Erika ^a   Hosali, Sharath ^c   Zhang, Li ^a,b,d   Hickman, Catherine ^a   Sunder Bansal, Shyam ^a   Cordero Reyes, Andrea M ^a   Geninatti, Thomas ^a   Sih, Juliana ^a   Goodall, Randy ^c   Palapattu, Ganesh ^b   Kloc, Malgorzata ^a,b   Ghobrial, Rafik M ^a,b   Ferrari, Mauro ^a,e,f,g   Grattoni, Alessandro ^a  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^b Texas and the Task Force on the ACGME Competencies   (United States)

^c NanoMedical Systems Inc   (United States)

^d TIANJIN MEDICAL UNIVERSITY   (China)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f Rice University   (United States)

^g Alliance for NanoHealth   (United States)

Author keywords

Drug delivery; Implantable device; Nanochannel; Transplantation

Indexed keywords

CHRONIC CONDITIONS; CHRONIC REJECTION; HUMAN GROWTH HORMONE; IMPLANTABLE DEVICES; NANO CHANNELS; PATHWAY INHIBITORS; THERAPEUTIC AGENTS; THERAPEUTIC EFFICACY;

IMPLANTS (SURGICAL); TRANSPLANTATION (SURGICAL);

DRUG DELIVERY;

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ACETYLSALICYLIC ACID; ALPHA2B INTERFERON; CYCLOSPORIN A; HUMAN GROWTH HORMONE; LETROZOLE; LEUPRORELIN; NANOCHANNEL; OCTREOTIDE;

ALGORITHM; ALLOGRAFT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIAC GRAFT REJECTION; CHRONIC GRAFT REJECTION; CONTROLLED STUDY; DOG; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; FEMALE; IN VIVO STUDY; LONG TERM CARE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT;

DRUG DELIVERY; IMPLANTABLE DEVICE; NANOCHANNEL; TRANSPLANTATION;

ANIMALS; DOGS; DRUG DELIVERY SYSTEMS; EQUIPMENT DESIGN; FEMALE; HUMANS; MALE; MEMBRANES, ARTIFICIAL; MICE; NANOSTRUCTURES; PHARMACEUTICAL PREPARATIONS; PROSTHESES AND IMPLANTS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84887164660     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2013.09.028     Document Type: Article

References (46)

1. J.H. Prescott, S. Lipka, S. Baldwin, N.F. Sheppard Jr., J.M. Maloney, J. Coppeta, B. Yomtov, M.A. Staples, and J.T. Santini Jr. Chronic, programmed polypeptide delivery from an implanted, multireservoir microchip device Nat. Biotechnol. 24 2006 437 438
2. J.L. Soriano, N. Batista, E. Santiesteban, M. Lima, J. Gonzalez, R. Garcia, Y. Zarza, M.V. Lopez, M. Rodriguez, J.L. Loys, N. Montejo, F. Aguirre, A. Macias, and A.M. Vazquez Metronomic cyclophosphamide and methotrexate chemotherapy combined with 1E10 anti-idiotype vaccine in metastatic breast cancer Int. J. Breast Cancer 2011 2011 710292
3. J. Duchier, F. Iannascoli, and M. Safar Antihypertensive effect of sustained-release isosorbide dinitrate for isolated systolic systemic hypertension in the elderly Am. J. Cardiol. 60 1987 99 102
4. M. Steiger Constant dopaminergic stimulation by transdermal delivery of dopaminergic drugs: a new treatment paradigm in Parkinson's disease Eur. J. Neurol. 15 2008 6 15
5. W. Shi, H. Gao, L. Xie, and S. Wang Sustained intraocular rapamycin delivery effectively prevents high-risk corneal allograft rejection and neovascularization in rabbits Invest. Ophthalmol. Vis. Sci. 47 2006 3339 3344
6. P.E. Goss, and K. Strasser-Weippl Prevention strategies with aromatase inhibitors Clin. Cancer Res. 10 2004 372S 379S
7. L.A. Mermel Bacteriology, safety and prevention of infection associated with continuous intravenous infusions Blood Coagul. Fibrinolysis 7 Suppl. 1 1996 S45 S51
8. H.B. Croxatto, J. Urbancsek, R. Massai, H.C. Bennink, A. van Beek, and the Implanon® Study Group* A multicentre efficacy and safety study of the single contraceptive implant Implanon ® Hum. Reprod. 14 1999 976 981
9. S. Mantripragada A lipid based depot (DepoFoam technology) for sustained release drug delivery Prog. Lipid Res. 41 2002 392 406
10. D.A. Bota, A. Desjardins, J.A. Quinn, M.L. Affronti, and H.S. Friedman Interstitial chemotherapy with biodegradable BCNU (Gliadel) wafers in the treatment of malignant gliomas Ther. Clin. Risk Manag. 3 2007 707 715
11. N.P. Corporation Product Information Sandostatin (Octreotide Acetate) for Injection 2012
12. H. Petersen, J. Bizec, H. Schuetz, and M. Delporte Pharmacokinetic and technical comparison of Sandostatin® LAR® and other formulations of long-acting octreotide BMC Res. Notes 4 2011 344
13. B.P.C.a.A. Corporation Viadur® (Leuprolide Acetate Implant), Viadur Prescribing Information 2005
14. R. Farra, N.F. Sheppard, L. McCabe, R.M. Neer, J.M. Anderson, J.T. Santini, M.J. Cima, and R. Langer First-in-human testing of a wirelessly controlled drug delivery microchip Sci. Transl. Med. 4 2012 1 10
15. D. Guillaume, A. Van Havenbergh, M. Vloeberghs, J. Vidal, and G. Roeste A clinical study of intrathecal baclofen using a programmable pump for intractable spasticity Arch. Phys. Med. Rehabil. 86 2005 2165 2171
16. C.H. Fang, P. Nathan, E.C. Robb, J.W. Alexander, and B.G. MacMillan Prospective clinical study of Hydron, a synthetic dressing, in delivery of an antimicrobial drug to second-degree burns J. Burn Care Rehabil. 8 1987 206 209
17. J.C. Wright Critical variables associated with nonbiodegradable osmotically controlled implants AAPS J. 12 2010 437 442
18. D. Fine, A. Grattoni, S. Hosali, A. Ziemys, E. De Rosa, J. Gill, R. Medema, L. Hudson, M. Kojic, M. Milosevic, L. Brousseau Iii, R. Goodall, M. Ferrari, and X. Liu A robust nanofluidic membrane with tunable zero-order release for implantable dose specific drug delivery Lab Chip 10 2010 3074 3083
19. A. Grattoni, E. De Rosa, S. Ferrati, Z. Wang, A. Gianesini, X. Liu, F. Hussain, R. Goodall, and M. Ferrari Analysis of a nanochanneled membrane structure through convective gas flow J. Micromech. Microeng. 19 2009
20. A. Grattoni, J. Gill, E. Zabre, D. Fine, F. Hussain, and M. Ferrari Device for rapid and agile measurement of diffusivity in micro- and nanochannels Anal. Chem. 83 2011 3096 3103
21. A. Ziemys, M. Kojic, M. Milosevic, N. Kojic, F. Hussain, M. Ferrari, and A. Grattoni Hierarchical modeling of diffusive transport through nanochannels by coupling molecular dynamics with finite element method J. Comput. Phys. 230 2011 5722 5731
22. A. Grattoni, D. Fine, E. Zabre, A. Ziemys, J. Gill, Y. Mackeyev, M.A. Cheney, D.C. Danila, S. Hosali, L.J. Wilson, F. Hussain, and M. Ferrari Gated and near-surface diffusion of charged fullerenes in nanochannels ACS Nano 5 2011 9382 9391
23. M. Marberger, A.V. Kaisary, N.D. Shore, G.S. Karlin, C. Savulsky, R. Mis, C. Leuratti, and J.R. Germa Effectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: a Phase III, open-label, international multicenter study Clin. Ther. 32 2010 744 757
24. M. Koltun, J. Nikolovski, K. Strong, D. Nikolic-Paterson, and W.D. Comper Mechanism of hypoalbuminemia in rodents Am. J. Physiol. Heart Circ. Physiol. 288 2005 H1604 H1610
25. Abbott Laboratories Prescribing Information for Lupron Depot (Luprolide Acetate for Depot Suspension) 2012
26. A. Santovena, J.B. Farina, M. Llabres, Y. Zhu, and P. Dannies Pharmacokinetics analysis of sustained release hGH biodegradable implantable tablets using a mouse model of human ovarian cancer Int. J. Pharm. 388 2010 175 180
27. A.M.o.t.R.G. Genentech Highlights of Product Information for Nutropin (Somatropin (rDNA Origin) for Injection 2012
28. D. Gilden Human growth hormone available for AIDS wasting GMHC Treat. Issues 9 1995 9 11
29. J. Cuzick Aromatase inhibitors for breast cancer prevention J. Clin. Oncol. 23 2005 1636 1643
30. I. Schering Corp. a subsidiary of Merk & Co. Product Information for Intron A 2011
31. Pfizer Highlights of Prescribing Information for Genotropin (Somatropin [rDNA Origin] for Injection) 2012
32. J.C. Wright, S. Tao Leonard, C.L. Stevenson, J.C. Beck, G. Chen, R.M. Jao, P.A. Johnson, J. Leonard, and R.J. Skowronski An in vivo/in vitro comparison with a leuprolide osmotic implant for the treatment of prostate cancer J. Control. Release 75 2001 1 10
33. C.L. Stevenson, J.T. Santini Jr., and R. Langer Reservoir-based drug delivery systems utilizing microtechnology Adv. Drug Deliv. Rev. 64 2012 1590 1602
34. M.C.T.a.N. Ventures Safety and Efficacy Study to Compare Continuous Infusion of Interferon with Standard of Care for Chronic Hepatitis C (COPE-HCV) 2009 National Library of Medicine (US) Bethesda (MD) (Available from: http://clinicaltrials.gov/ct2/show/NCT00919633 NLM Identifier:NCT00919633, [Cited 2012])
35. S.C. Hall, M.M. Tan, J.J. Leonard, and C.L. Stevenson Characterization and comparison of leuprolide degradation profiles in water and dimethyl sulfoxide J. Pept. Res. 53 1999 432 441
36. J.L. Cleland, A. Mac, B. Boyd, J. Yang, E.T. Duenas, D. Yeung, D. Brooks, C. Hsu, H. Chu, V. Mukku, and A.J. Jones The stability of recombinant human growth hormone in poly(lactic-co-glycolic acid) (PLGA) microspheres Pharm. Res. 14 1997 420 425
37. L. Ruiz, N. Reyes, L. Duany, A. Franco, K. Aroche, and E. Hardy Rando Long-term stabilization of recombinant human interferon alpha 2b in aqueous solution without serum albumin Int. J. Pharm. 264 2003 57 72
38. N.N.Z. Limited New Zealand Data Sheet: Femara (Letrozole) 2.5 mg Film-coated Tablets 2011
39. S. Navea, A. de Juan, and R. Tauler Three-way data analysis applied to multispectroscopic monitoring of protein folding Anal. Chim. Acta. 446 2001 187 197
40. L.F. Huang, and W.Q. Tong Impact of solid state properties on developability assessment of drug candidates Adv. Drug Deliv. Rev. 56 2004 321 334
41. M. Vicente-Manzanares, and F. Sanchez-Madrid Role of the cytoskeleton during leukocyte responses Nat. Rev. Immunol. 4 2004 110 122
42. T.S. Skelton, N. Tejpal, Y. Gong, M. Kloc, and R.M. Ghobrial Downregulation of RhoA and changes in T cell cytoskeleton correlate with the abrogation of allograft rejection Transpl. Immunol. 23 2010 185 193
43. S. Ohki, K. Iizuka, S. Ishikawa, M. Kano, K. Dobashi, A. Yoshii, Y. Shimizu, M. Mori, and Y. Morishita A highly selective inhibitor of Rho-associated coiled-coil forming protein kinase, Y-27632, prolongs cardiac allograft survival of the BALB/c-to-C3H/He mouse model J. Heart Lung Transplant. 20 2001 956 963
44. P.L. Tharaux, R.C. Bukoski, P.N. Rocha, S.D. Crowley, P. Ruiz, C. Nataraj, D.N. Howell, K. Kaibuchi, R.F. Spurney, and T.M. Coffman Rho kinase promotes alloimmune responses by regulating the proliferation and structure of T cells J. Immunol. 171 2003 96 105
45. H. Nakagawa, K. Yoshioka, E. Miyahara, Y. Fukushima, M. Tamura, and K. Itoh Intrathecal administration of Y-27632, a specific rho-associated kinase inhibitor, for rat neoplastic meningitis Mol. Cancer Res. 3 2005 425 433
46. R. Farra, N.F. Sheppard Jr., L. McCabe, R.M. Neer, J.M. Anderson, J.T. Santini Jr., M.J. Cima, and R. Langer First-in-human testing of a wirelessly controlled drug delivery microchip Sci. Transl. Med. 4 2012 122ra121